ST. JOSEPH, Mich., Oct. 3 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, announced today that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of new biomarkers implicated in breast cancer based on network analysis. The research program includes a novel large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore(TM), GeneGo's flagship data mining platform.
"We are very happy to receive this Phase II award from NCI in the current highly competitive environment as it validates our commitment to scientific research and our novel, innovative ideas in pathway analysis," said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. "In Phase I, we made some exciting new findings in sub-categorization of breast cancers based on network analysis of previously published microarray expression data. However, the biomarkers found in such 'meta-analysis' have to be validated in a new design study in a stringent clinical environment. We are pleased to collaborate with Mayo Clinic, a world leading institution in clinical and research oncology. The microarray and genotyping assays will be conducted at Mayo labs, and the analysis will be performed with state-of-the-art translational medicine and systems biology tools."
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
